Symbols

QURE

uniQure·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About QURE

Uniqure N.V.

A leading gene therapy company that develops innovative treatments for genetic diseases

Industry

Biological Technology

Established Date

01/09/2012

Listing Date

02/05/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

221

Fiscal Year Ends

12-31

Website

www.uniqure.com

Security Type

Common stock

Office address

Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands

Business

Introduction

UniQure N.V. was established as a private limited liability company on January 9, 2012 in accordance with the relevant provisions of the Dutch law. The company is a biotechnology company specializing in gene therapy, dedicated to the development of a single treatment pathway for rare and critically ill patients. Its pipeline includes clinical drug candidates for Huntington's disease, amyotrophic lateral sclerosis associated with SOD 1 mutations, refractory median temporal lobe epilepsy and Fabry disease, reflecting the focus on advancing innovative therapies in the field of gene therapy.

Company Financials

EPS

QURE has released its 2025 Q4 earnings. EPS was reported at -0.57, versus the expected -0.92, beating expectations. The chart below visualizes how QURE has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

QURE has released its 2025 Q4 earnings report, with revenue of 5.57M, reflecting a YoY change of 6.65%, and net profit of -37.09M, showing a YoY change of 49.38%. The Sankey diagram below clearly presents QURE's revenue sources and cost distribution.